Enzymotec, which develops lipid-based nutritional ingredients and medical foods, raised $62 million by offering 4.4 million shares at $14, below the range of $16 to $18. Enzymotec plans to list on the NASDAQ under the symbol ENZY. BofA Merrill Lynch and Jefferies acted as lead managers on the deal.
